多发性骨髓瘤自体造血细胞移植中普乐沙福节省动员方案的分析 - Suppr

Analysis of a plerixafor sparing mobilization regimen for autologous hematopoietic cell transplant in multiple myeloma.

作者信息

Cancilla Daniel, Nurse Daniel Paul, Wei Wei, Cenin Danielle, Ferraro Christina, D'Andrea Christopher, Matia Brian, Coffman Julie, Hamilton Betty K, Srivastava Swati, Sauter Craig, Williams Louis, Khouri Jack

机构信息

Blood and Marrow Transplant Program, Taussig Cancer Center, Cleveland Clinic, Cleveland, OH, USA.

Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA.

出版信息

Ann Hematol. 2024 Dec;103(12):6027-6030. doi: 10.1007/s00277-024-05935-1. Epub 2024 Aug 13.

DOI:10.1007/s00277-024-05935-1

PMID:39136773

Abstract

摘要

相似文献

Analysis of a plerixafor sparing mobilization regimen for autologous hematopoietic cell transplant in multiple myeloma.多发性骨髓瘤自体造血细胞移植中普乐沙福节省动员方案的分析

Ann Hematol. 2024 Dec;103(12):6027-6030. doi: 10.1007/s00277-024-05935-1. Epub 2024 Aug 13.

Are we choosing mobilization regimens for autologous stem cell transplantation in multiple myeloma wisely: A single center comparison of GCSF+/-plerixafor vs cyclophosphamide/GCSF+/-plerixafor.我们是否明智地选择了多发性骨髓瘤自体干细胞移植的动员方案：GCSF+/-plerixafor 与环磷酰胺/GCSF+/-plerixafor 的单中心比较。

J Clin Apher. 2022 Aug;37(4):348-353. doi: 10.1002/jca.21976. Epub 2022 Feb 26.

Mobilization of peripheral blood stem cells for autologous transplant in non-Hodgkin's lymphoma and multiple myeloma patients by plerixafor and G-CSF and detection of tumor cell mobilization by PCR in multiple myeloma patients.通过培洛昔琼和 G-CSF 动员非霍奇金淋巴瘤和多发性骨髓瘤患者的外周血干细胞进行自体移植，并通过 PCR 检测多发性骨髓瘤患者的肿瘤细胞动员情况。

Bone Marrow Transplant. 2010 Feb;45(2):269-75. doi: 10.1038/bmt.2009.142. Epub 2009 Jul 13.

Mobilization strategies with and without plerixafor for autologous stem cell transplant in patients with multiple myeloma.在多发性骨髓瘤患者的自体干细胞移植中使用和不使用普乐沙福的动员策略。

Bone Marrow Transplant. 2024 Oct;59(10):1440-1448. doi: 10.1038/s41409-024-02385-1. Epub 2024 Jul 31.

Plerixafor and granulocyte colony-stimulating factor for first-line steady-state autologous peripheral blood stem cell mobilization in lymphoma and multiple myeloma: results of the prospective PREDICT trial.培洛昔福联合粒细胞集落刺激因子在淋巴瘤和多发性骨髓瘤一线稳定期自体外周血造血干细胞动员中的应用：前瞻性 PREDICT 试验结果。

Haematologica. 2013 Feb;98(2):172-8. doi: 10.3324/haematol.2012.071456. Epub 2012 Sep 14.

Autologous peripheral blood stem cell mobilization and collection in patients with lymphoma and multiple myeloma: A single-center experience using the plerixa for pre-emptive approach.淋巴瘤和多发性骨髓瘤患者的自体外周血干细胞动员和采集：采用普乐沙福进行抢先治疗的单中心经验。

Saudi Med J. 2022 Jun;43(6):626-632. doi: 10.15537/smj.2022.43.6.20210912.

Low baseline platelet count predicts poor response to plerixafor in patients with multiple myeloma undergoing autologous stem cell mobilization.基线血小板计数低预测多发性骨髓瘤患者自体干细胞动员后对plerixafor 反应不良。

Cytotherapy. 2020 Jan;22(1):16-20. doi: 10.1016/j.jcyt.2019.10.008. Epub 2019 Dec 24.

[Efficiency and safety analysis of Plerixafor combined with granulocyte colony-stimulating factor on autologous hematopoietic stem cell mobilization in lymphoma].普乐沙福联合粒细胞集落刺激因子用于淋巴瘤患者自体造血干细胞动员的有效性及安全性分析

Zhonghua Xue Ye Xue Za Zhi. 2023 Feb 14;44(2):112-117. doi: 10.3760/cma.j.issn.0253-2727.2023.02.005.

Stem Cell Mobilization for Multiple Myeloma Patients Receiving Daratumumab-Based Induction Therapy: A Real- World Experience.接受基于达雷妥尤单抗诱导治疗的多发性骨髓瘤患者的干细胞动员：一项真实世界经验

Transplant Cell Ther. 2023 May;29(5):340.e1-340.e4. doi: 10.1016/j.jtct.2023.02.013. Epub 2023 Feb 19.

Plerixafor as first- and second-line strategies for autologous stem cell mobilization in patients with non-Hodgkin's lymphoma or multiple myeloma.培洛昔福作为非霍奇金淋巴瘤或多发性骨髓瘤患者自体干细胞动员的一线和二线策略。

Pharmacotherapy. 2012 Jul;32(7):596-603. doi: 10.1002/j.1875-9114.2012.01096.x.

本文引用的文献

Anti-CD38 monoclonal antibody impairs CD34+ mobilization and affects clonogenic potential in multiple myeloma patients.抗 CD38 单克隆抗体可损害多发性骨髓瘤患者 CD34+细胞的动员，并影响其集落形成能力。

Blood Transfus. 2024 Jul;22(4):328-337. doi: 10.2450/BloodTransfus.667.

Hematopoietic stem cell mobilization.造血干细胞动员

Tzu Chi Med J. 2021 Oct 21;34(3):270-275. doi: 10.4103/tcmj.tcmj_98_21. eCollection 2022 Jul-Sep.

Cost saving, patient centered algorithm for progenitor cell mobilization for autologous hematopoietic cell transplantation.用于自体造血细胞移植的祖细胞动员的成本节约、以患者为中心的算法。

J Clin Apher. 2021 Aug;36(4):553-562. doi: 10.1002/jca.21892. Epub 2021 Mar 12.

Evaluation of the predictive value of the hematopoietic progenitor cell count using an automated hematology analyzer for CD34+ stem cell mobilization and apheresis product yield.采用自动化血液分析仪评估造血祖细胞计数对 CD34+ 干细胞动员和单采产品产量的预测价值。

Int J Lab Hematol. 2020 Apr;42(2):170-179. doi: 10.1111/ijlh.13142. Epub 2019 Dec 12.

Stem cell mobilization in poor mobilizers with multiple myeloma or lymphoma before and after introduction of plerixafor: a single-center comparative analysis using a cost-efficient single fixed-dose schedule.普乐沙福引入前后多发性骨髓瘤或淋巴瘤低动员者的干细胞动员：使用经济高效的单一固定剂量方案的单中心比较分析

Leuk Lymphoma. 2018 Jul;59(7):1722-1725. doi: 10.1080/10428194.2017.1393673. Epub 2017 Oct 30.

Successful peripheral blood stem cell mobilization with a cost-efficient single fixed-dose plerixafor schedule in poor mobilizers.在动员效果不佳的患者中，采用具有成本效益的单一固定剂量普乐沙福方案成功实现外周血干细胞动员。

Leuk Lymphoma. 2017 Aug;58(8):1849-1858. doi: 10.1080/10428194.2016.1271946. Epub 2017 Jan 13.

Effect of lenalidomide therapy on mobilization of peripheral blood stem cells in previously untreated multiple myeloma patients.来那度胺治疗对既往未经治疗的多发性骨髓瘤患者外周血干细胞动员的影响。

Leukemia. 2008 Jun;22(6):1280-1; author reply 1281-2. doi: 10.1038/sj.leu.2405035. Epub 2007 Nov 22.

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.大剂量化疗联合造血干细胞救援治疗多发性骨髓瘤。

N Engl J Med. 2003 May 8;348(19):1875-83. doi: 10.1056/NEJMoa022340.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Analysis of a plerixafor sparing mobilization regimen for autologous hematopoietic cell transplant in multiple myeloma.

作者信息

机构信息

出版信息

相似文献

本文引用的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

本文引用的文献